Volume 66, Issue 4 pp. 508-516

Original Article

Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma

Min Jong Kim,

Min Jong Kim

Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea

Search for more papers by this author

Mi Jin Gu,

Corresponding Author

Mi Jin Gu

Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea

Address for correspondence: M J Gu, Department of Pathology, Yeungnam University College of Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu 705-717, Korea. e-mail: [email protected]Search for more papers by this author

Hee-Kyung Chang,

Hee-Kyung Chang

Department of Pathology, Kosin University College of Medicine, Busan, Korea

Search for more papers by this author

Eunsil Yu,

Eunsil Yu

Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Search for more papers by this author

Min Jong Kim,

Min Jong Kim

Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea

Search for more papers by this author

Mi Jin Gu,

Corresponding Author

Mi Jin Gu

Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea

Hee-Kyung Chang,

Hee-Kyung Chang

Department of Pathology, Kosin University College of Medicine, Busan, Korea

Search for more papers by this author

Eunsil Yu,

Eunsil Yu

Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Search for more papers by this author

First published: 14 November 2014

https://doi.org/10.1111/his.12566

Citations: 18

Share a link

Email
Wechat
Bluesky

Abstract

Aims

To investigate AT-rich interactive domain-containing protein 1A (ARID1A) and p53 expression in small intestinal carcinoma (SIC) and to determine its prognostic significance.

Methods and results

Immunohistochemical staining for ARID1A and p53 was performed in 178 SICs using a tissue microarray (TMA). Loss of or low ARID1A expression was observed in 36 (20.2%) and 60 (33.7%) of cases, respectively. Aberrant p53 expression was observed in 99 (55.6%) cases. Loss of or low ARID1A expression was found to be associated with signet ring cell carcinoma and undifferentiated carcinoma, a high-grade tumour, and a higher T stage. No relationship was found between aberrant p53 expression and clinicopathological factors or overall survival. Patients with loss of ARID1A expression, irrespective of p53 expressional status, showed significantly poorer overall survival than those expressing ARID1A. Multiple regression analysis revealed that grade and pT stage were associated significantly with ARID1A loss, and multivariate analysis showed that patients with high ARID1A expression had a lower risk of death than those with loss of ARID1A expression.

Conclusions

Low or loss of ARID1A expression is correlated significantly with a high-grade tumour, higher T stage, and poorer overall survival. These findings suggest that ARID1A expression could be used as a prognostic marker in SIC.

References

1Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014; 64; 9–29.
10.3322/caac.21208
CAS PubMed Web of Science® Google Scholar
2Chang HK, Yu E, Kim J et al. Adenocarcinoma of the small intestinal: a multi-institutional study of 197 surgically resected cases. Hum. Pathol. 2010; 41; 1087–1096.
10.1016/j.humpath.2010.01.006
PubMed Web of Science® Google Scholar
3Cobrin GM, Pittman RH, Lewis BS. Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer 2006; 107; 22–27.
10.1002/cncr.21975
PubMed Web of Science® Google Scholar
4Arber N, Hibshoosh H, Yasui W et al. Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. Cancer Epidemiol. Biomarkers Prev. 1999; 8; 1101–1105.
CAS PubMed Web of Science® Google Scholar
5Blaker H, Helmchen B, Bonisch A et al. Mutational activation of the RAS-RAF-MAPK and the wnt pathway in small intestinal adenocarcinomas. Scand. J. Gastroenterol. 2004; 39; 748–753.
10.1080/00365520410005847
PubMed Web of Science® Google Scholar
6Sutter T, Arber N, Moss SF et al. Frequent K-ras mutations in small bowel adenocarcinomas. Dig. Dis. Sci. 1996; 41; 115–118.
10.1007/BF02208591
CAS PubMed Web of Science® Google Scholar
7Wheeler JM, Warren BF, Mortensen NJ et al. An insight into the genetic pathway of adenocarcinoma of the small intestinal. Gut 2002; 50; 218–223.
10.1136/gut.50.2.218
CAS PubMed Web of Science® Google Scholar
8Gu MJ, Kim JY, Park JB. Fascin expression predicts lymph node metastasis and worse survival in small intestinal carcinoma. Pathology 2014; 46; 21–24.
10.1097/PAT.0000000000000024
CAS PubMed Web of Science® Google Scholar
9Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011; 11; 481–492.
10.1038/nrc3068
CAS PubMed Web of Science® Google Scholar
10Guan B, Wang TL, Shih I. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011; 71; 6718–6727.
10.1158/0008-5472.CAN-11-1562
CAS PubMed Web of Science® Google Scholar
11Lowery WJ, Schildkraut JM, Akushevich L et al. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int. J. Gynecol. Cancer 2012; 22; 9–14.
10.1097/IGC.0b013e318231f140
PubMed Web of Science® Google Scholar
12Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT. Loss of ARID1A expression and its relationship with PI3K–akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod. Pathol. 2013; 27; 983–990.
10.1038/modpathol.2013.216
CAS PubMed Web of Science® Google Scholar
13Jones S, Li M, Parsons DW et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum. Mutat. 2012; 33; 100–103.
10.1002/humu.21633
CAS PubMed Web of Science® Google Scholar
14Agrawal N, Jiao Y, Bettegowda C et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012; 2; 899–905.
10.1158/2159-8290.CD-12-0189
CAS PubMed Web of Science® Google Scholar
15Wang DD, Chen YB, Pan K et al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012; 7; e40364.
10.1371/journal.pone.0040364
CAS PubMed Web of Science® Google Scholar
16Fujimoto A, Totoki Y, Abe T et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 2012; 44; 760–764.
10.1038/ng.2291
CAS PubMed Web of Science® Google Scholar
17Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 2011; 43; 875–878.
10.1038/ng.907
CAS PubMed Web of Science® Google Scholar
18Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosom. Cancer 2007; 46; 745–750.
10.1002/gcc.20459
CAS PubMed Web of Science® Google Scholar
19Bosse T, ter Haar NT, Seeber LM et al. Loss of ARID1A expression and its relationship with PI3K–akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod. Pathol. 2013; 26; 1525–1535.
10.1038/modpathol.2013.96
CAS PubMed Web of Science® Google Scholar
20Wiegand KC, Lee AF, Al-Agha OM et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 2011; 224; 328–333.
10.1002/path.2911
CAS PubMed Web of Science® Google Scholar
21Wang K, Kan J, Yuen ST et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 2011; 43; 1219–1223.
10.1038/ng.982
CAS PubMed Web of Science® Google Scholar
22Maeda D, Mao TL, Fukayama M et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int. J. Mol. Sci. 2010; 11; 5120–5128.
10.3390/ijms11125120
CAS PubMed Web of Science® Google Scholar
23Vousden KH, Lane DP. P53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007; 8; 275–283.
10.1038/nrm2147
CAS PubMed Web of Science® Google Scholar
24Fadare O, Renshaw IL, Liang SX. Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J. Cancer 2012; 3; 129–136.
10.7150/jca.4140
CAS PubMed Web of Science® Google Scholar
25Fadare O, Gwin K, Desouki MM et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod. Pathol. 2013; 26; 1101–1110.
10.1038/modpathol.2013.35
CAS PubMed Web of Science® Google Scholar
26Allo G, Bernardini MQ, Wu RC et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod. Pathol. 2014; 27; 255–261.
10.1038/modpathol.2013.144
CAS PubMed Web of Science® Google Scholar
27Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH. Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum. Pathol. 2013; 44; 1365–1374.
10.1016/j.humpath.2012.11.007
CAS PubMed Web of Science® Google Scholar
28Zhang Y, Xu X, Zhang M et al. ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosis. Tumour Biol. 2014; 35; 5701–5707.
10.1007/s13277-014-1755-x
CAS PubMed Web of Science® Google Scholar
29Wiegand KC, Sy K, Kalloger SE et al. ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Hum. Pathol. 2014; 45; 1258–1268.
10.1016/j.humpath.2014.02.006
CAS PubMed Web of Science® Google Scholar
30Chou A, Toon CW, Clarkson A et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum. Pathol. 2014; 45; 1697–1703.
10.1016/j.humpath.2014.04.009
CAS PubMed Web of Science® Google Scholar
31Huang HN, Lin MC, Tseng LH et al. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression and ARID1A expression. Histopathology 2014. Doi: 10.1111/his.12543.
10.1111/his.12543
Google Scholar
32Gu MJ, Bae YK, Kim A et al. Expression of hMLH1, hMSH2 and hMSH6 in small intestinal carcinomas. Hepatogastroenterology 2012; 59; 2228–2232.
PubMed Web of Science® Google Scholar
33Nishiyama K, Yao T, Yonemasu H, Yamaguchi K, Tanaka M, Tsuneyoshi M. Overexpression of p53 protein and point mutation of K-ras genes in primary carcinoma of the small intestinal. Oncol. Rep. 2002; 9; 293–300.
PubMed Web of Science® Google Scholar
34Svrcek M, Jourdan F, Sebbagh N et al. Immunohistochemical analysis of adenocarcinoma of the small intestinal: a tissue microarray study. J. Clin. Pathol. 2003; 56; 898–903.
10.1136/jcp.56.12.898
CAS PubMed Web of Science® Google Scholar
35Brueckl WM, Heinze E, Milsmann C et al. Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestinal. Cancer Lett. 2004; 203; 181–190.
10.1016/j.canlet.2003.08.013
CAS PubMed Web of Science® Google Scholar
36Mao TL, Shih IM. The roles of ARID1A in gynecologic cancer. J. Gynecol. Oncol. 2013; 24; 376–381.
10.3802/jgo.2013.24.4.376
CAS PubMed Web of Science® Google Scholar
37Mao TL, Ardighieri L, Ayhan A et al. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am. J. Surg. Pathol. 2013; 37; 1342–1348.
10.1097/PAS.0b013e3182889dc3
PubMed Web of Science® Google Scholar
38Rahman M, Nakayama K, Rahman MT et al. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. Hum. Pathol. 2013; 44; 103–109.
10.1016/j.humpath.2012.04.021
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume66, Issue4

March 2015

Pages 508-516

Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma

Abstract

Aims

Methods and results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma

Abstract

Aims

Methods and results

Conclusions

References

Citing Literature

References

Related

Information